RR-11a

• UNSPSC Description:

  RR-11a is a synthetic enzyme inhibitor of Legumain (IC50=31-55 nM). RR-11a can be used for the research of cancer and acute myocardial infarction (AMI)[1][2][3].

• Target Antigen:

  Legumain

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/RR-11a.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@@H](C)C(N[C@@H](C)C(NN(CC(N)=O)C(/C=C/C(ON1C(CCC1=O)=O)=O)=O)=O)=O)OCC2=CC=CC=C2

• Molecular Weight:

  560.51

• References & Citations:

  [1]Liao D, et al. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine. 2011 Dec;7(6):665-73.|[2]Ralph A, et al. Nanoparticle-based tumor-targeted drug delivery. Patent: CA2809617C|[3]Yang H, et al. Legumain is a predictor of all-cause mortality and potential therapeutic target in acute myocardial infarction. Cell Death Dis. 2020;11(11):1014. Published 2020 Nov 26.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1361390-56-8